A multicenter, double-blind, one-year study comparing safety and efficacy of Atorvastatin versus Simvastatin in patients with hypercholesterolemia

Dart, Anthony, Jerums, George, Nicholson, Geoffrey, d'Emden, Michael, Hamilton-Craig, Ian, Tallis, George, Best, James, West, Malcolm, Sullivan, David, Bracs, Peter and Black, Donald (1997) A multicenter, double-blind, one-year study comparing safety and efficacy of Atorvastatin versus Simvastatin in patients with hypercholesterolemia. American Journal of Cardiology, 80 1: 39-44. doi:10.1016/S0002-9149(97)00280-4


Author Dart, Anthony
Jerums, George
Nicholson, Geoffrey
d'Emden, Michael
Hamilton-Craig, Ian
Tallis, George
Best, James
West, Malcolm
Sullivan, David
Bracs, Peter
Black, Donald
Title A multicenter, double-blind, one-year study comparing safety and efficacy of Atorvastatin versus Simvastatin in patients with hypercholesterolemia
Journal name American Journal of Cardiology   Check publisher's open access policy
ISSN 0002-9149
1879-1913
Publication date 1997-07
Sub-type Article (original research)
DOI 10.1016/S0002-9149(97)00280-4
Volume 80
Issue 1
Start page 39
End page 44
Total pages 6
Place of publication Bridgewater, NJ, United States
Publisher Excerpta Medica
Language eng
Abstract We directly compared the safety and efficacy of atorvastatin and simvastatin in hypercholesterolemic patients. This 1-year, randomized, double-blind study was performed at 9 community- and university-based research hospitals in Australia. One-hundred seventy-seven patients between the ages of 18 and 80 years with baseline low-density-lipoprotein (LDL) cholesterol ≤4.14 and ≤7.76 mmol/L (160 and 300 mg/dl, respectively) and triglycerides ≤4.52 mmol/L (400 mg/dl) received once-daily dosing with atorvastatin (Lipitor) 10 mg or simvastatin (Zocor) 10 mg. At week 16, the dose of medication was titrated to atorvastatin 20 mg or simvastatin 20 mg if patients did not meet LDL cholesterol target of ≤ 3.36 mmol/L (130 mg/dl). Efficacy was reported as percent change from baseline in LDL cholesterol, total cholesterol, very low density lipoprotein cholesterol, total triglycerides, high-density lipoprotein cholesterol, apolipoproteins Al and B, and lipoprotein(a). Atorvastatin caused significantly greater reductions from baseline than did simvastatin for LDL cholesterol, total cholesterol, very low density lipoprotein cholesterol, triglycerides, and apolipoprotein B (p <0.05). No patient in either treatment group had clinically important elevations in creatine phosphokinase, alanine amino-transaminase, or aspartate aminotransaminase. No serious adverse events were considered associated with treatment. With atorvastatin 10 mg, 46% of the patients achieved LDL cholesterol target goal by week 16, whereas only 27% of the simvastatin patients achieved the target goal at the 10-mg dose. This cholesterol-lowering profile affords utility in many patient types.
Keyword Coronary heart disease
Plasma
Cholesterol
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 159 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 188 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 24 May 2011, 14:55:23 EST by System User on behalf of Rural Clinical School